Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is a clinical-stage biopharmaceutical company with a strong portfolio of clinical-stage assets targeting depressive disorders and schizophrenia populations. Their approach to redefine psychiatry through personalized and effective treatment options shows potential for success. Although a delay in the readout timing of ALTO-100 and ALTO-300 may cause disappointment, it does not significantly impact the company's valuation. With a quarterly burn of ~$22M, the company is on track to achieve its cash runway guidance through 2029. Alto's focus on biomarker analysis and commercial differentiation strategies could position them for success in a competitive market. However, there are risks to achieving target prices, including clinical and regulatory challenges and the unproven nature of their biomarker approach.

Bears say

Alto Neuroscience is a clinical-stage biopharmaceutical company with a high degree of clinical and regulatory risk. Their precision psychiatry platform has potential, but it has yet to be proven and their drug candidates such as ALTO-100 and ALTO-101 have had limited success in clinical trials. The company will also face financial and commercial risks as they continue to develop and commercialize their therapies. Their current valuation is based on forward assumptions and third-party reliance, making it uncertain and potentially overvalued in the long-term.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.